TriSalus Life Sciences, Inc. (TLSI)

Over the past six months, TriSalus Life Sciences' stock has been impacted by several events. The company reported earnings reports, including preliminary unaudited financial results for Q4 and full year 2025, and reaffirmed its 2026 revenue guidance. TriSalus announced its intention to offer and sell shares of its common stock in an underwritten public offering. Richard Marshall, M.D., was appointed as Chief Medical Officer, and Michael Stansky was appointed to the Board of Directors. TriSalus announced the publication of data demonstrating enhanced delivery and immune activation with Nelitolimod. As of April 10, 2026, the share price was $4.22, representing a decline compared to the previous year.

The provided information does not contain specific details regarding demand seasonality for TriSalus Life Sciences, Inc.'s products and services. The nature of oncology treatments and medical devices typically suggests a more consistent demand driven by patient needs and medical advancements rather than seasonal fluctuations.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company dedicated to transforming outcomes for patients with solid tumors, particularly in the liver and pancreas. The company integrates innovative drug delivery technology with standard-of-care therapies and its investigational immunotherapeutic, utilizing its proprietary Pressure-Enabled Drug Delivery (PEDD) approach. Key products include the TriNav Infusion System, Pancreatic Retrograde Venous Infusion System, and Nelitolimod (SD-101).

TriSalus Life Sciences, Inc. is headquartered in Westminster, Colorado, United States, with its operations and market primarily focused within the United States.

TriSalus Life Sciences maintains a reputation as an innovative oncology-focused medical technology company. Positive clinical data, advancements in technology, reimbursement coverage, and strategic appointments have contributed to its reputation. Data demonstrated enhanced delivery and immune activation with Nelitolimod. The company experienced continued strong commercial momentum and expanded use of the TriNav platform. CMS announced HCPCS code C8004, which expanded reimbursement coverage for mapping procedures using TriNav. The appointment of experienced professionals enhanced confidence in the company's leadership and strategic direction.

TriSalus Life Sciences, Inc. has a significant institutional ownership presence, with 66 institutional owners and shareholders holding a total of 11,385,815 shares. Major institutional owners include Nantahala Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Individual insider shareholders include Acquisition Sponsor Llc Medtech, James Emmett Young, Mats Wahlstrom, and others. Insider buying has outpaced selling in the past three months.